Navigation Links
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Date:9/3/2009

SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a business overview at the following conferences:

-- Thomas Weisel Partners 2009 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 9th at 3:50 p.m. EDT.

-- Rodman & Renshaw 11th Annual Healthcare Conference at the Palace Hotel in New York on Thursday, September 10th at 12:05 p.m. EDT.

There will be a live webcast of the presentations, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm. The webcasts will be available for replay through October 10th, 2009.

About Pharmacyclics

Pharmacyclics((R)) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us athttp://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics, Inc. Rights Offering Oversubscribed
2. Pharmacyclics Announces Subscription Price for Rights Offering
3. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
4. Pharmacyclics Files Registration Statement for Rights Offering
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
7. Pharmacyclics Secures $5.0 Million in Debt Financing
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... The recent vote by the American Medication Association to align with the World ... hopefully sheds new light on the way health insurers, governments and the public view ... of Texas Fertility Center . , “This designation is something we have ...
(Date:6/27/2017)... ... June 27, 2017 , ... Biodex Medical Systems, Inc. announces ... in one device. This assistive aid lifts patients safely from a seated to a ... lift mechanics. The Mobility Assist is the latest in a line of Biodex products ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced ... production and fermentation process. The efficiencies created by the newest strain design ... notably the ethanol industry wherein individual production plants are planning to invest upwards ...
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners Chairman ... Director of Product Development R&D at Allergan and CMC expert with more than ... and established biopharma companies, has joined the firm as an Expert Consultant. ...
Breaking Biology Technology:
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):